IPB the place to be: raised funds will further Gwydion oil potential

|

Published 18-APR-2019 13:28 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

IPB Petroleum Ltd (ASX:IPB) has received firm subscriptions for a placement of approximately 23.75 million new shares to be issued at 4.0 cents per share to institutional, professional and sophisticated investors both domestically and internationally.

Completion of the placement should increase the company’s funds from $380,000 at the end of March to approximately $1.3 million, providing important capital to progress its activities in the Browse Basin.

Proceeds of the placement will be used to progress drilling, planning and testing works for WA-424-P prior to a final investment decision being made, as well as requisite regulatory approval applications, environmental planning, engineering studies and commercial negotiations and proposed debt funding activities.

The proposed Idris well is aimed at testing a potentially large up-dip stratigraphic extension of the existing Gwydion oil discovery within IPB’s 100% owned WA-424-P permit P50 Prospective Resource 70MMBBLS recoverable.

The injection of funds will also assist in financing ongoing permit study work, seismic processing and farmout related activities at the prospect which is located in the Browse Basin in relatively close proximity to other major projects.

DLT activity examines Gwydion discovery

IPB has completed initial concept and feasibility studies.

The WA-424-P Project is currently at pre-FID stage awaiting regulatory approvals and will be subject to a successful debt financing which is estimated to take around 4 months.

IPB is currently arranging debt finance up to US$80 million to fund its Drilling, Logging and Testing (DLT) program.

This project has the objective of delineating the upside resources available, or identified with the original Gwydion oil discovery.

The company has gone out to tender for drill rig, well testing and well services and other suppliers, and anticipates having agreements in-place subject to financing by mid-year with major supplies.

IPB has also appointed Atoll Financial to arrange international debt finance for the project.

The map below illustrates IPB’s permits in the Browse Basin, including the Idris Prospect and its close proximity to Icthys and Burnside.

Icthys, in particular, points to significant upside for IPB.

If IPB is not successful in progressing the DLT Project, it still has the option to continue to pursue farm-out of an interest to carry on its exploration/appraisal well Idris to test the up-dip extension of the existing Gwydion oil discovery.

Having renewed its WA-424-P permit containing the Gwydion oil discovery last June, IPB has until mid-2021 to commence drilling the subject well under title conditions.

Management has previously reported strong interest in its ongoing farmout project over the past 12 months, with several companies providing positive feedback and technical validation in relation to the Idris Prospect.

For a number of strategic or commercial reasons some parties elected not to continue with the process at this point in time.

The improving macro-economic outlook for oil prices largely due to under investment in exploration and appraisal activities in recent years should provide an opportunity for interested parties to once again pursue commercial opportunities such as a farm-in to IPB’s WA-424-P Permit.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X